Affiliation:
1. Center for Anti-Infective Research and Development, Hartford, Connecticut 06102
Abstract
ABSTRACT
We describe the activity of a novel cephalosporin, CXA-101 (FR26 4205), against a panel of highly resistant
Pseudomonas aeruginosa
isolates collected from U.S. hospitals. CXA-101 demonstrated increased potency against this population of resistant isolates, with activity that is 4- to 10-fold higher than that of comparator agents in each phenotypic category. The addition of tazobactam did not improve its activity. CXA-101 appears to be a promising addition to the category of antipseudomonal β-lactams.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献